A recent study calls into question the safety of mirtazapine in the elderly, an antidepressant often recommended in the elderly for treatment of senile cachexia due to the medication’s appetite stimulation properties. This episode reviews the SYMBAD trial with guest Sarah Grady, PharmD.
Sarah Grady, PharmD
Redeem your CPE or CME credit here!
Need a membership?
References and resources: Banerjee S, High J, Stirling S, et al. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet. 2021 Oct 23;398(10310):1487-1497. doi: 10.1016/S0140-6736(21)01210-1. PMID: 34688369; PMCID: PMC8546216.
Continuing Education Information:
Dr. Sarah Grady reports no actual or potential conflicts of interest associated with this episode.
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-401-H01-P
Initial release date: 12/20/21
Expiration date: 12/20/22
Additional CPE & CME details can be found here (www.ceimpact.com/podcast)